Bayer 将来の成長

Future 基準チェック /36

Bayer利益と収益がそれぞれ年間50.6%と2.2%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に16.1% 56.2%なると予測されています。

主要情報

50.6%

収益成長率

56.21%

EPS成長率

Pharmaceuticals 収益成長	27.3%
収益成長率	2.2%
将来の株主資本利益率	16.15%
アナリストカバレッジ	Good
最終更新日	16 Apr 2026

今後の成長に関する最新情報

Bayer Aktiengesellschaft (ETR:BAYN) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 14

Recent updates

The Market Lifts Bayer Aktiengesellschaft (ETR:BAYN) Shares 29% But It Can Do More

Jan 27

Further Upside For Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Introduce Price Risks After 27% Bounce

Dec 03

Bayer Aktiengesellschaft (ETR:BAYN) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 14

Is Bayer (ETR:BAYN) A Risky Investment?

Jul 13

Innovative Launches And Decisive Moves Set Stage For Remarkable Growth In Pharmaceuticals And Consumer Health

Nov 24 Pharmaceutical and agriculture innovations are key strategies for growth, offsetting generic competition and boosting future revenues.

業績と収益の成長予測

XTRA:BAYN - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2028	48,397	3,565	3,960	7,187	13
12/31/2027	46,533	2,987	3,434	7,326	18
12/31/2026	45,285	1,917	-1,960	1,498	17
12/31/2025	45,575	-3,620	3,443	5,930	N/A
9/30/2025	45,866	-198	3,937	6,725	N/A
6/30/2025	46,174	-3,418	4,594	7,151	N/A
3/31/2025	46,579	-3,253	5,783	8,503	N/A
12/31/2024	46,606	-2,552	4,590	7,368	N/A
9/30/2024	46,739	-880	5,303	7,978	N/A
6/30/2024	47,113	-1,266	5,690	8,443	N/A
3/31/2024	47,013	-3,119	3,786	6,517	N/A
12/31/2023	47,637	-2,941	2,366	5,117	N/A
9/30/2023	47,775	-3,667	-508	2,571	N/A
6/30/2023	48,714	1,448	-473	2,649	N/A
3/31/2023	50,489	3,037	1,203	4,269	N/A
12/31/2022	50,739	4,150	4,144	7,093	N/A
9/30/2022	49,857	4,700	4,313	7,078	N/A
6/30/2022	48,357	4,239	4,547	7,235	N/A
3/31/2022	46,392	2,202	4,497	7,128	N/A
12/31/2021	44,081	1,000	2,478	5,089	N/A
9/30/2021	42,958	222	430	2,794	N/A
6/30/2021	41,683	-7,565	-314	1,950	N/A
3/31/2021	40,883	-14,849	11	2,367	N/A
12/31/2020	41,400	-15,569	2,485	4,903	N/A
9/30/2020	42,155	-15,995	4,805	7,398	N/A
6/30/2020	43,479	-7,303	4,940	7,713	N/A
3/31/2020	44,138	2,631	4,253	6,899	N/A
12/31/2019	43,545	2,391	5,557	8,207	N/A
9/30/2019	43,150	-1,530	N/A	7,929	N/A
6/30/2019	42,581	287	N/A	7,698	N/A
3/31/2019	39,856	557	N/A	8,338	N/A
12/31/2018	36,742	1,374	N/A	7,917	N/A
9/30/2018	34,983	6,027	N/A	7,218	N/A
6/30/2018	33,747	3,237	N/A	7,878	N/A
3/31/2018	34,473	3,486	N/A	7,951	N/A
12/31/2017	35,015	3,249	N/A	8,134	N/A
9/30/2017	35,242	3,087	N/A	8,597	N/A
6/30/2017	35,475	3,924	N/A	8,939	N/A
3/31/2017	32,769	3,991	N/A	8,608	N/A
12/31/2016	34,943	3,743	N/A	9,089	N/A
9/30/2016	37,405	3,837	N/A	8,234	N/A
6/30/2016	40,151	3,971	N/A	7,511	N/A
3/31/2016	46,146	4,210	N/A	7,488	N/A
12/31/2015	46,085	4,025	N/A	6,890	N/A
9/30/2015	45,592	3,616	N/A	7,243	N/A
6/30/2015	44,555	3,429	N/A	6,729	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BAYNは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 1.7% ) よりも高い成長率であると考えられます。

収益対市場: BAYN今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: BAYN今後 3 年以内に収益を上げることが予想されます。

収益対市場: BAYNの収益 ( 2.2% ) German市場 ( 6.1% ) よりも低い成長が予測されています。

高い収益成長: BAYNの収益 ( 2.2% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BAYNの自己資本利益率は、3年後には低くなると予測されています ( 16.1 %)。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/04/20 15:18
終値	2026/04/17 00:00
収益	2025/12/31
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Bayer Aktiengesellschaft 18 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。40

アナリスト	機関
Rafael Bonardell Trianes	Banco de Sabadell. S.A.
Emily Field	Barclays
Charles Pitman	Barclays

Bayer 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Price target increased by 14% to €39.87

Price target increased by 7.6% to €34.18

Price target increased by 7.4% to €31.21

Bayer Aktiengesellschaft (ETR:BAYN) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Price target decreased by 7.8% to €32.06

Recent updates

Upcoming dividend of €0.11 per share

Bayer AG Announces Appointment of Nelson Ambrogio as President of U.S. Pharmaceuticals, Effective May 1, 2026

Bayer Announces Kerendia Meets Primary Endpoint In Investigational Phase III Find-Ckd Study In Patients With Non-Diabetic Chronic Kidney Disease

Bayer Aktiengesellschaft to Report Q4, 2026 Results on Feb 24, 2027

Bayer Aktiengesellschaft to Report Q3, 2026 Results on Nov 03, 2026

Dividend of €0.11 announced

Missouri Court Grants Preliminary Approval of Roundup Class Settlement to Resolve Current and Future Claims

Full year 2025 earnings: EPS misses analyst expectations

Bayer Aktiengesellschaft, Annual General Meeting, Apr 24, 2026

Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

Bayer Announces XOFIGO (Radium-223 Dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit In PEACE-3 Trial In Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases

Monsanto Announces Roundup™ Class Settlement Agreement to Resolve Current and Future Claims

Bayer's Asundexian Demonstrated A Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo

Bayer to Present Results from Phase III Oceanic-Stroke Study of Asundexian in Secondary Stroke Prevention

The Market Lifts Bayer Aktiengesellschaft (ETR:BAYN) Shares 29% But It Can Do More

Price target increased by 14% to €39.87

Askbio Inc. Announces Fda Acceptance of Investigational New Drug (Ind) Application for Ab-1009 Gene Therapy for Treatment of Late-Onset Pompe Disease

Price target increased by 7.6% to €34.18

Bayer Starts Phase IIa Study for Treatment of Patients with Alport Syndrome

Further Upside For Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Introduce Price Risks After 27% Bounce

Price target increased by 7.4% to €31.21

Bayer Starts New Phase III Study with Mirena®? for the Treatment of Nonatypical Endometrial Hyperplasia

Bayer Announces Positive Topline Results from the Global Phase III Study Oceanic-Stroke, with Its Investigational, Once Daily, Oral FXIa Inhibitor asundexian

U.S. FDA Approves HYRNUO®? (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Bayer Aktiengesellschaft to Report Q2, 2026 Results on Aug 04, 2026

Bayer Aktiengesellschaft (ETR:BAYN) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Third quarter 2025 earnings: EPS misses analyst expectations

Bayer AG Announces Chief Financial Officer Changes

Bayer Announces New Phase III Investigational Data from the Pivotal Fine-One Trial

Bayer Announces U.S. Food and Drug Administration Approval for Moderate to Severe Hot Flashes Due to Menopause

Hesperos and Bayer Consumer Health Develop First Human-On-A-Chip Model of Stress-Induced Cognitive Dysfunction

Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson's Disease

Bayer®? Aspirin Introduces Aspirina to the U.S. Pain Market

Bayer Aktiengesellschaft to Report Q1, 2026 Results on May 12, 2026

Second quarter 2025 earnings: EPS misses analyst expectations

Bayer Aktiengesellschaft to Report Q3, 2025 Results on Nov 12, 2025

Is Bayer (ETR:BAYN) A Risky Investment?

Bayer Ag and BlueRock Therapeutics LP Announces First Patient Receives Investigational Therapy in Phase 1/2a Clinical Trial of OpCT-001 for the Treatment of Primary Photoreceptor Diseases

Bayer Announces Executive Changes for North America

Bayer Files for Approval of Gadoquatrane to the US Food and Drug Administration

U.S. FDA Approves Third Indication of Darolutamide for Patients with Advanced Prostate Cancer

Vividion Therapeutics, Inc. and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor

Elinzanetant Significantly Reduces Frequency of Moderate to Severe Vasomotor Symptoms Associated with Endocrine Therapy for Breast Cancer in Phase III Oasis-4 Study as Per Bayer

Bayer's XOFIGO (Radium-223 Dectloride) Combination Data Showcases Clinical Benefits in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases

Bayer Highlights New Data from Oncology and Women’S Health Portfolios At 2025 Asco Annual Meeting

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Bayer Initiates Phase I Study Targeting GPC3 with Actinium-225 Radiopharmaceutical in Patients with Advanced Hepatocellular Carcinoma

Bayer Announces Changes to CFO for Crop Science Division, Effective July 1, 2025

Upcoming dividend of €0.11 per share

Bayer to Unveil Latest NUBEQA®? (Darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting

Bayer Receives Full FDA Approval For VITRAKVI®? As First-In-Class TRK Inhibitor

Elliott Reportedly Gauge Investor Interest in Bayer's Consumer Health Business

Bayer Announces Management Changes, Effective April 15, 2025

Bayer Announces U.S. FDA Accepts Supplemental New Drug Application Under Priority Review for New Indication for KERENDIA®? (Finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of 40%

Dividend of €0.11 announced

Full year 2024 earnings: EPS misses analyst expectations

Bayer Introduces Vyconic Soybeans at Commodity Classic 2025

Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking New Indication for KERENDIA® (finerenone)

Bayer Announces Positive Topline Results of Phase Iii Study Oasis 4 Investigating Elinzanetant

Bayer Submits Application in China for Third Indication of Darolutamide

Bayer Aktiengesellschaft to Report Q2, 2025 Results on Aug 06, 2025

Innovative Launches And Decisive Moves Set Stage For Remarkable Growth In Pharmaceuticals And Consumer Health

Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF =40% at AHA 2024

Price target decreased by 7.8% to €32.06

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Bayer and Liveo Research Launches Blister Packaging with Improved Environmental Footprint

Bayer Submits Application for Third Indication of Darolutamide in the EU

U.S. Food and Drug Administration Accepts New Drug Application for Bayer's Elinzanetant

Bayer Ag and BlueRock Therapeutics LP Announces Positive 24-Month Data from exPDite

Bayer Submits Application to U.S. FDA for Third Indication of darolutamide